From: Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review
Age (year) | ||
---|---|---|
Mean ± SD | 68.5 ± 5.6 | |
PSA at diagnosis (ng/mL) | ||
Mean ± SD | 7.2 ± 2.6 | |
10 or less | 144 | |
10-20 | 25 | |
Clinical T stage | ||
T1c | 143 | |
T2a | 16 | |
T2b | 7 | |
T2c | 1 | |
Ne | 2 | |
Gleason score | ||
4-6 | 166 | |
7 | 2 | |
Ne | 1 | |
Neoadjuvant ADT | ||
No | 125 | |
Yes | 42 | |
Ne | 2 | |
IPSS at baseline | ||
Mean ± SD | 6.3 ± 4.0 (*) | |
Follow-up period (months) | ||
Mean (range) | 50 (1–85 months) |